Stifel Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $73
Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)
Incyte Price Target Raised to $60.00/Share From $55.00 by Deutsche Bank
Deutsche Bank Adjusts Incyte Price Target to $60 From $55, Maintains Hold Rating
Argus Adjusts Price Target on Incyte to $75 From $70
Express News | Incyte Corporation : Deutsche Bank Raises Target Price to $60 From $55
Incyte Corporation Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
Incyte Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)
Incyte's Strong Product Performance and Growth Trajectory Merit a Buy Rating
Citigroup Maintains Buy on Incyte, Raises Price Target to $88
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
Incyte Is Maintained at Sector Perform by RBC Capital
Express News | Incyte Shares Are Trading Lower After the Company Reported Mixed Q2 Financial Results. The Stock Initially Traded Higher but It Has Since Reversed
JPMorgan Adjusts Price Target on Incyte to $61 From $59
A Quick Look at Today's Ratings for Incyte(INCY.US), With a Forecast Between $80 to $88
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Day One Biopharmaceuticals (DAWN) and Incyte (INCY)
Truist Financial Sticks to Its Buy Rating for Incyte (INCY)
B of A Securities Maintains Neutral on Incyte, Raises Price Target to $66
Incyte Analyst Ratings
No Data